PETROVAX LOAN MAY HELP COMMERCIALISE NEW, INNOVATIVE MEDICINES
June 1st, 2011
BY MJ DESCHAMPS
THE EUROPEAN Bank for Reconstruction & Development (EBRD) is considering lending Russian pharmaceutical company NOP Petrovax Pharm up to Euro EUR15.8 million to help commercialise three new innovative medicines fighting immunology and viral diseases.
Petrovax focuses on patented medicines. Rusnano (the Russian Corporation of Nanotechnologies) is considering participating in the project.
ENDS
THE EUROPEAN Bank for Reconstruction & Development (EBRD) is considering lending Russian pharmaceutical company NOP Petrovax Pharm up to Euro EUR15.8 million to help commercialise three new innovative medicines fighting immunology and viral diseases.
Petrovax focuses on patented medicines. Rusnano (the Russian Corporation of Nanotechnologies) is considering participating in the project.
ENDS
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.